GLAXF News and Press, GlaxoSmithKline Plc From 04/19/24

2024-04-19 04:02:55 ET Summary GSK trades at lower price multiples compared to competitors due to weaker pipeline. GSK's revenue growth in 2023 was modest, but it has strong performers in its product mix. GSK needs to demonstrate the effectiveness and efficiency of its pipelin...

2024-04-17 01:50:40 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-04-16 18:25:52 ET Summary Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results ...

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

2024-04-12 14:12:23 ET Summary Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with...

2024-04-11 10:40:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. or the first quarter of 2024, Aristotl...

2024-03-11 12:54:07 ET GSK plc (GSK) TD Cowen 44th Annual Health Care Conference March 4, 2024, 2:50 pm ET Company Participants Luke Miels - CCO Conference Call Participants Stephen Scala - TD Cowen Presentation Stephen Scala Well, good af...

2024-03-11 08:22:37 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-02-23 16:52:40 ET Summary Moderna, Inc.'s market share for the Spikevax vaccine is increasing, but the company faces a tough 2024 with expected revenue slumps. The new respiratory vaccine has questioned efficacy and is late to market, potentially impacting the sales potential...

2024-02-16 07:30:00 ET Summary Dividend income from my taxable account totaled $1,013.35. This represents a 12.1% increase in passive income compared to January 2023. The markets may swing wildly from week to week and month to month, but dividends are seemingly more stable, re...